BioSpace News Archive

Galmed announces positive late-stage results in biopsy-proven NASH patients.

A letter published Wednesday in the NEJM links a stroke patient’s death to lecanemab. Eisai investigators respond.

NovoCure’s novel cancer-fighting platform hits the mark in non-small cell lung cancer.

Metagenomi announced a Series B extension financing round led by Moderna, Leaps by Bayer and several others.

BioSpace’s exclusive Hotbed Maps highlights nine different regions to watch across the U.S. The maps, made in vibrant color for BioSpace showcases a one-of-a-kind glance at some of 2023’s headline-making companies.

InnoCare Pharma announced that the Company will present the latest clinical data of FGFR inhibitor gunagratinib for the treatment of cholangiocarcinoma at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 19-21, 2023, which will be held online and offline in San Francisco, U.S.

Diaccurate announced it received from Bpifrance a grant termed “Aide à l’Innovation” to support its DIACC2020 Program aiming to establish the preclinical proof-of-concept of its sole-in-class molecule DIACC2010 as a next-generation payload for ADCs, for the treatment of solid and hematologic tumors.

2022 has been a breakthrough year for ANGLE with the world’s first FDA product clearance for a system to harvest cancer cells from patient blood for subsequent analysis following a sustained effort by the Company for over six years including extensive dialogue and formal pre-submissions with FDA, and the submission of over 400 technical reports and documents and processing of over 16,000 samples to demonstrate system performance.

Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, is partnering with Turbine,* a tech-enabled biotech leveraging its proprietary Simulated Cell™ platform to solve complex diseases.

Azafaros B.V. announced that it has received Investigational New Drug clearance from the United States Food and Drug Administration to conduct a clinical Phase 2 trial for its lead asset, AZ-3102, for the treatment of GM2 gangliosidosis and Niemann-Pick disease type C.